Oxford Biomedica and Beam Therapeutics sign CAR-T deal
Agreement will utilise Oxford Biomedica’s LentiVector platform
Read More
Tag: Oxford Biomedica
Sanofi hands back rights to Oxford Biomedica gene therapies
The move follows a portfolio review by the French drug giant
Read More
Oxford Biomedica and VMIC announce collaboration
The five-year deal will see the parties work collaboratively to facilitate the manufacture of viral vector based vaccines
Read More
Oxford Biomedica bags MHRA nod for two manufacturing suites
The move will provide access to the Oxford COVID-19 Vaccine Consortium for production of vaccine should trials prove successful
Read More
Oxford Biomedica, Santen enter retinal disease R&D alliance
Inherited retinal diseases are ideal candidates for gene therapy because many of the responsible genetic mutations have already been identified.
Read More
Oxford BioMedica unveils digital initiative to streamline manufacturing
UK gene and cell therapy group Oxford BioMedica has announced a new digital framework initiative to streamline the production of next-generation medicines.
Read More
FDA panel backs Novartis’ CAR-T therapy CTL019
Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel.
Read More
Oxford BioMedica signs major supply deal with Novartis
Oxford BioMedica has sealed a major deal with Novartis to supply the Swiss drug giant with lentiviral vectors used to create cell therapy products, including CTL019 and other undisclosed Chimeric Antigen Receptor T cell (CART) products.
Read More
UK biotechs link in gene therapy deal
Oxford BioMedica has secured a collaboration and license agreement with fellow UK biotech Orchard Therapeutics centred on developing gene therapies for orphan diseases.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
